Selecta Biosciences Announces $50 Million Private Placement

posted in: News | 0

Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses, today announced that it has entered into definitive agreements to sell securities in a private placement that is expected … Continued

SQZ Biotech Named a 2017 WEF Technology Pioneer

posted in: News | 0

Today SQZ Biotech, a pre-clinical stage biotechnology company developing cell therapies, announced it was selected as a member of the 2017 class of World Economic Forum Technology Pioneers. SQZ is one of only thirty companies selected and was recognized for … Continued

Twist Bioscience Raises Additional $27 Million

posted in: News | 0

Twist Bioscience Corporation, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today announced that it raised an additional $27 million in venture financing. This close, combined with the $33 million announced in March 2017, completes the $60 … Continued

ARMO BioSciences Announces Encouraging Survival Data Observed in Patients with Advanced Pancreatic Cancer in Phase 1/1b Trial of Immunotherapy AM0010

posted in: News | 0

ARMO BioSciences, Inc., a late-stage immuno-oncology  company, today announced clinical data on its lead investigational immuno-oncology drug AM0010 (pegilodecakin, PEGylated Interleukin-10) in combination with FOLFOX chemotherapy for the treatment of patients with advanced pancreatic cancer. These data are being presented in … Continued

ARMO BioSciences Announces Promising Response Rates and Survival Data in Patients with Advanced NSCLC and RCC from Phase 1/1b Trial for Immunotherapy AM0010 with Checkpoint Inhibitors

posted in: News | 0

ARMO BioSciences, Inc., a late-stage immuno-oncology  company, today announced clinical data on its lead investigational immuno-oncology drug AM0010 (pegilodecakin, PEGylated Interleukin-10) in combination with immune checkpoint inhibitors for the treatment of patients with advanced non-small cell lung cancer (NSCLC) and metastatic … Continued